Dishman Carbogen (DCAL) | Stock Overview & Key Data
Dishman Carbogen Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹396.40 on January 22, 2018
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dishman Carbogen
DCAL
|
26.50B Small-cap | -2.24% | -7.21% | 9.02% | -19.76% | -29.73% | -33.95% | 46.77% | -6.77% | 33.46% | 290.77% | 118.12% |
|
Biocon
BIOCON
|
566.52B Large-cap | 1.66% | -3.27% | 10.34% | 6.50% | 7.30% | 17.90% | 71.09% | 5.03% | 250.57% | 603.49% | 1,357.39% |
|
OneSource Specialty
ONESOURCE
|
202.76B Large-cap | -6.58% | -11.52% | 8.72% | 0.44% | -9.19% | -20.38% | -5.70% | -5.70% | -5.70% | -5.70% | -5.70% |
|
Zota Health Care
ZOTA
|
39.41B Small-cap | 3.68% | 3.22% | 14.06% | -26.10% | -17.99% | 27.17% | 243.00% | 632.12% | 1,248.00% | 1,248.00% | 1,248.00% |
|
Panacea Biotec
PANACEABIO
|
21.84B Small-cap | -2.19% | 39.94% | 70.71% | 51.42% | 43.20% | 18.85% | 307.76% | 44.67% | 440.21% | 276.43% | 141.23% |
|
Titan Bio-Tech
TITANBIO
|
19.90B Small-cap | 3.09% | -1.02% | 28.03% | 96.24% | 110.92% | 419.45% | 756.94% | 499.88% | 6,742.31% | 9,962.22% | 20,395.39% |
Ownership & Short Interest
Calculate Your Dishman Carbogen Investment Returns
Long-Term Investment Performance Analysis
Dishman Carbogen stock price in Jul 2016 was ₹146.55, A ₹1,000.00 lump sum investment in Dishman Carbogen made 9 years ago would be worth approximately ₹1,229.89 today, representing a positive return of 22.99%. This translates to an annualized return (CAGR) of 2.11%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is DCAL's 52-week high and low?
- In the last 52 weeks, Dishman Carbogen reached a high of ₹321.95 (on September 23, 2025) and a low of ₹128.50 (on March 30, 2026).
- What is the market cap and P/E ratio for DCAL?
- Curious about Dishman Carbogen's size and valuation? Its market capitalization stands at 26.50B. When it comes to valuation, the P/E ratio (trailing twelve months) is 22.30, and the forward P/E (looking ahead) is 13.52.
- Does DCAL pay dividends? If so, what's the yield?
- As for dividends, Dishman Carbogen isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Dishman Carbogen's main competitors or similar companies to consider before investing?
When looking at Dishman Carbogen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON566.52B Healthcare Biotechnology 17.90% 71.09% OneSource Specialty
ONESOURCE202.76B Healthcare Biotechnology -20.38% -5.70% Zota Health Care
ZOTA39.41B Healthcare Biotechnology 27.17% 243.00% Panacea Biotec
PANACEABIO21.84B Healthcare Biotechnology 18.85% 307.76% Titan Bio-Tech
TITANBIO19.90B Healthcare Biotechnology 419.45% 756.94% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dishman Carbogen Amcis Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Dishman Carbogen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 0.06%, the Debt to Equity ratio from the most recent quarter is 40.20, and its Gross Profit Margin stands at 80.34%.
- What is the recent revenue and earnings growth for DCAL?
- Looking at Dishman Carbogen's growth, its revenue over the trailing twelve months (TTM) was INR28B. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.50%, and quarterly earnings saw a YoY growth of -8.78%.
- How much of DCAL stock is held by insiders and institutions?
- Wondering who owns Dishman Carbogen stock? Company insiders (like executives and directors) hold about 69.30% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 2.41%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.